Find the latest Novo Nordisk A/S (NVO) stock quote, history, news and other vital information to help you with your stock trading and investing.

See Novo Nordisk A/S (NVO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Novo Nordisk A/S (NVO)’s share was trading at $84.03 as of Jan 29th. NVO’s trailing and forward P/E were 28.32 and 21.88 respectively according to Yahoo Finance.

Jan 1, 2025 · NVO is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected to grow 19.6% year-over-year for the current fiscal year, with sales growth of 20.5%.

Dec 24, 2024 · Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its next-generation subcutaneous obesity candidate, CagriSema.

Jan 30, 2025 · In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently talked about.

Jan 18, 2025 · Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent to finish at $78.69 after following news that the company’s ...

Interactive Chart for Novo Nordisk A/S (NVO), analyze all the data with a huge range of indicators.

Jan 7, 2025 · In the latest trading session, Novo Nordisk (NVO) closed at $83.34, marking a -1.99% move from the previous day. This move lagged the S&P 500's daily loss of 1.11%.

Jan 9, 2025 · Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.